AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9029752
Drug: 0.75-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75-g dose of vigabatrin in renal failure patients
Trial: 8498730
Drug: terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 60 mg/pseudoephedrine hydrochloride 120 mg (T/Ps)
Trial: 8498730
Drug: clemastine fumarate
RxNorm normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clemastine fumarate 1.34 mg/phenylpropanolamine 75 mg (C/Ph)
Trial: 3278574
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sublingual nifedipine (group 1)
Trial: 31957334
Drug: TDM-guided dosing
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDM-guided dosing
Trial: 31957334
Drug: Current practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current practice (160 mg/m2)
Trial: 31455386
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 0 μg.ml ‐1
Trial: 31455386
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 0.5 μg.ml ‐1
Trial: 31455386
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 1.0 μg.ml ‐1
Trial: 16108508
Drug: Topical anti-histamine/decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anti-histamine/decongestant eye drops
Trial: 12126869
Drug: Amisulpride (400‐800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (400‐800 mg/day, n = 339)
Trial: 12126869
Drug: Haloperidol (15‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (15‐20 mg/day, n = 160)
Trial: 12126869
Drug: Risperidone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (8 mg/day, n = 113)
Trial: 7806817
Drug: Continuous splinting
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous splinting (early treatment)
Trial: 7806817
Drug: Continuous splinting
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous splinting (delayed treatment)
Trial: 2699608
Drug: Tranylcypromine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranylcypromine (5 mg once a day)
Trial: 30579342
Drug: Tetracaine mucilage
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracaine mucilage in combination with image illustration on CRBD
Trial: 25415158
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (450 mg per day)
Trial: 19036079
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG (ara‐C = 7590 mg/m2)
Trial: 19036079
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (ara‐C) therapy with IDA‐DCTER (ara‐C = 800 mg/m2)
Trial: 19036079
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG
Trial: 19036079
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (ara‐C) therapy
Trial: 17935765
Drug: salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol/fluticasone propionate combination (SFC)
Trial: 15300807
Drug: Serum PSA
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PSA < 3 ng/ml
Trial: 15300807
Drug: Serum PSA
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PSA 3.0-3.9 ng/ml with benign digital rectal examination or free total PSA ratio > or = 0.16
Trial: 8208391
Drug: Phentolamine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (35 mg) after saline infusion
Trial: 8208391
Drug: Phenylephrine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (500 micrograms) after saline infusion
Trial: 2146057
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 mg every 8 hours)
Trial: 2592580
Drug: Labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200 mg every 12 hours)
Trial: 30048414
Drug: Simulated sunlight
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated sunlight (1.3× standard erythemal dose in T‐shirt and shorts, three times per week for 4 wk and then once per week for 8 wk)
Trial: 30048414
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 (1000 IU·d for 4 wk and then 400 IU·d for 8 wk)
Trial: 18683001
Drug: SDA-SBO (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDA-SBO (24 ml/day providing approximately 3.7 g SDA)
Trial: 18683001
Drug: EPA (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (approximately 1 g/day)
Trial: 7554393
Drug: IL-6 administered
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 administered by daily subcutaneous injection for 7 days at a dose level of 1, 3, or 10 micrograms/kg/day
Trial: 2254511
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CB)
Trial: 2254511
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control (WL) after treatment
Trial: 2254511
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CB) at 10-week follow-up
Trial: 7437255
Drug: Oxyfedrine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxyfedrine (maximum dose 32 mg three times daily)
Trial: 7437255
Drug: Propranolol (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (maximum dose 120 mg three times daily)
Trial: 17158441
Drug: Policosanol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol (20 mg)
Trial: 2824365
Drug: Lithium countertransport
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium countertransport in hypertensive adults treated with antihypertensive medications
Trial: 26507862
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg of rhBMP‐7 (Osigraft OP1) on a type I collagen carrier
Trial: 22933541
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 10 μg/d
Trial: 22933541
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 30 μg/d
Trial: 22933541
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 40 μg/d
Trial: 22933541
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 μg/d)
Trial: 22933541
Drug: Control (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (30 μg/d)
Trial: 22933541
Drug: Control (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (40 μg/d)
Trial: 15722809
Drug: Daily pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pain duration
Trial: 15722809
Drug: Daily mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mean VAS scores
Trial: 11973381
Drug: Composite solution
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite solution I (amphipathic lipids)
Trial: 11973381
Drug: Composite solution
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite solution II (amphipathic lipids)
Trial: 8133112
Drug: Indirect immunofluorescent
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect immunofluorescent antibody (IFA) test for detection of Babesia microti antibody
Trial: 797057
Drug: Dental procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dental procedures (extraction, filling therapy, prosthodontic procedures)
Trial: 28445659
Drug: Adalimumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (20 mg or 40 mg according to body weight, administered subcutaneously every 2 weeks)
Trial: 25537159
Drug: Afatinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (50 mg daily)
Trial: 25537159
Drug: Lapatinib (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1500 mg daily)
Trial: 25537159
Drug: Trastuzumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (4 mg/kg loading dose, then 2 mg/kg/week)
Trial: 19556536
Drug: Erythropoietin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin at any dose
Trial: 17492951
Drug: Intravenous FFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous FFA infusion (intralipid/heparin infusion 4 h)
Trial: 17492951
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration (0.5 mg i.v.)
Trial: 17492951
Drug: GHR blockade
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHR blockade (pegvisomant, 30 mg s.c.)
Trial: 15352967
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Propacetamol (2 g) and Diclofenac (75 mg)
Trial: 1089446
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg daily
Trial: 1089446
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg three times a week
Trial: 30949710
Drug: Oral Δ9‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Δ9‐tetrahydrocannabinol (THC)
Trial: 24262217
Drug: Periodic Presumptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodic Presumptive Treatment (PPT)
Trial: 17532774
Drug: RinsEndo-system; 5‐mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RinsEndo-system; 5‐mL NaOCl, 50 s
Trial: 17532774
Drug: Flushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flushing with a syringe; 5‐mL NaOCl, 1 min
Trial: 11952508
Drug: IVAA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVAA 500 mg twice weekly for 8 weeks
Trial: 11952508
Drug: IVAA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVAA 500 mg/week for 8 weeks (Group 1)
Trial: 11952508
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (Group 2)
Trial: 11952508
Drug: Initial phase
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial phase IVAA treatment
Trial: 266313
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy consisting of cytarabine and 6-thioguanine for two days each month
Trial: 21150914
Drug: Intravenous THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous THC (1.25 mg)
Trial: 15499961
Drug: Prediction rule
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction rule based on nine independent risk factors (gender, birthweight, educational level of the father, S. pneumoniae, cerebrospinal fluid leukocyte count, delay between admission and start of antibiotics, dexamethasone use, seizures treated with anticonvulsive therapy, prolonged fever)
Trial: 11180763
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (neoadjuvant chemotherapy)
Trial: 9131311
Drug: Furosemide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1.0 mg/kg/day)
Trial: 9131311
Drug: Furosemide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1.0 mg/kg/day) plus Metolazone (0.2 mg/kg/day)
Trial: 8482455
Drug: Albendazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (10 mg.kg‐1.day‐1 for 8 weeks)
Trial: 8482455
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of percutaneous drainage and albendazole
Trial: 3436158
Drug: 2.4 mega
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mega units procaine penicillin plus 1 g probenacid
Trial: 25483417
Drug: Single loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single loading dose only
Trial: 22317882
Drug: Hyoscine N-butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N-butylbromide (1 mL, 20 mg IV)
Trial: 22834281
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl solution)
Trial: 20047622
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM)-based therapy
Trial: 17207103
Drug: 12-step treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-step treatment program
Trial: 12823777
Drug: Antibodies (rituximab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies (rituximab, alemtuzumab)
Trial: 12823777
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of antibodies with chemotherapy
Trial: 12823777
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies and transplantation (autologous and allogeneic)
Trial: 8522226
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol at a rising dose of 2 to 8 mg, totaling 16 mg over 20 days
Trial: 8522226
Drug: Intravaginal estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal estriol 0.03 mg/day for 10 days and 0.06 mg/day for 10 days
Trial: 1415824
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day of alprazolam
Trial: 1415824
Drug: 6 mg/day
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/day of alprazolam
Trial: 1415824
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day or 6 mg/day of alprazolam
Trial: 3922207
Drug: Sustained-release nitroglycerin
RxNorm normalized name: nitroglycerin Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nitroglycerin
Trial: 3094356
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nitroglycerin and diltiazem
Trial: 21378596
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily energy intake during the first week of life
Trial: 16543739
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release oral morphine (SROM)
Trial: 14651723
Drug: Fexofenadine (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (180 mg)
Trial: 7825540
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g flaxseed/d for 4 wk
Trial: 7825540
Drug: Muffins containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muffins containing 25 g flaxseed
Trial: 26293067
Drug: 4% Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% Gelofusine (GEL group)
Trial: 8487823
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate 100 mg/kg/day for up to 5 days
Trial: 8487823
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate 150 mg/kg/day for up to 5 days
Trial: 2962623
Drug: Sufentanil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 15 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Trial: 2962623
Drug: Sufentanil 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 7.5 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Trial: 2962623
Drug: Bupivacaine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Trial: 27074172
Drug: Less invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less invasive surfactant administration (beractant 4 ml/kg)
Trial: 27074172
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (intubation, surfactant administration, early extubation)
Trial: 20718927
Drug: 300IR five-grass
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300IR five-grass pollen SLIT tablets
Trial: 17928199
Drug: Contrast injections
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injections (5 injections per patient)
Trial: 17928199
Drug: Contrast injections
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injections (11 injections per patient)
Trial: 17928199
Drug: Increasing number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing number of contrast injections
Trial: 15962735
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with RF treatment (ThermaCool TC, Thermage)
Trial: 15962735
Drug: No anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anesthesia with RF treatment
Trial: 10384193
Drug: Antegrade pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antegrade pulmonary artery flushing with alprostadil and modified Euro‐Collins solution
Trial: 8639011
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (250 mg/mo intramuscular depot injection of Sustanon)
Trial: 29510234
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BT‐A) injection (200 units) into the gastrocnemius muscle
Trial: 26891611
Drug: Saw Palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw Palmetto (SP) at 960 mg daily
Trial: 22008269
Drug: Alcohol condition
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol condition (0.7 g pure ethanol/kg body weight)
Trial: 15126001
Drug: Lipo‐PGE1 (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipo‐PGE1 (10mg in 20ml of saline, injected intravenously as a bolus once daily for 2 weeks)
Trial: 11669407
Drug: CHF 1035
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 1035 (10 mg/day)
Trial: 7527591
Drug: Cisplatin/5-FU chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/5-FU chemotherapy
Trial: 7527591
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin/5-FU) with radiotherapy
Trial: 2691278
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 400 micrograms b.i.d.
Trial: 31441407
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human high mobility group box 1 (rhHMGB1) treatment group (100 μg/L rhHMGB1)
Trial: 31441407
Drug: UFH pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH pretreatment group (10 kU/L UFH + 100 μg/L rhHMGB1)
Trial: 31441407
Drug: UFH control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH control group (10 kU/L UFH)
Trial: 25520366
Drug: Zinc-fortified oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc-fortified oral rehydration solution (3 mg Zn)